Plus Therapeutics, Inc. Sustainability Profile
Plus Therapeutics, Inc., headquartered in the United States, is a pioneering biotechnology company focused on developing innovative therapies for cancer treatment. Founded in 2016, the company has made significant strides in the field of radiopharmaceuticals, particularly with its lead product, Rhenium-186 NanoLiposome, designed for targeted cancer therapy. With a commitment to advancing treatment options, Plus Therapeutics operates primarily in the oncology sector, leveraging its proprietary technology to enhance the delivery of therapeutic agents. The company has garnered attention for its unique approach to radiotherapy, positioning itself as a leader in the development of next-generation cancer treatments. Notable achievements include successful clinical trials that underscore its potential to improve patient outcomes in challenging cancer types.
DitchCarbon Score
How does Plus Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Plus Therapeutics, Inc.'s score of 23 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Plus Therapeutics, Inc.'s reported carbon emissions
Plus Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established any specific reduction targets or initiatives related to climate commitments. Without emissions data or defined climate strategies, it is challenging to assess their environmental impact or commitments within the industry context. As such, Plus Therapeutics appears to be in the early stages of developing a comprehensive approach to carbon management and sustainability.
How Carbon Intensive is Plus Therapeutics, Inc.'s Industry?
How Carbon Intensive is Plus Therapeutics, Inc.'s Location?
Plus Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Plus Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
